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WHAT THIS PAPER ADDS
 In 2009, the ESVS published clinical practice guidelines for the invasive treatment of carotid disease. Two years later, 14 societies
published guidelines that are in sharp contrast with the ESVS guidelines. The aim of this review was to assess the validity of the
ESVS guidelines on carotid stenting based on the evidence available today. Moreover, a meta-analysis of all randomised controlled
trials (RCTs) comparing carotid artery stenting (CAS) with carotid endarterectomy (CEA) was performed separately for symptomatic
and asymptomatic patients. Such a meta-analysis is presented in the literature for the ﬁrst time. In summary, this review andmeta-
analysis
1. Conﬁrms that CEA is preferable, in terms of stroke prevention, to CAS for the majority of symptomatic patients with carotid
stenosis;
2. Questions the role of CAS in asymptomatic patients;
3. Provides an abbreviated review of the evidence about CAS; and
4. Prompts for an update of the ESVS guidelines.a r t i c l e i n f o
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Background and purpose: Many medical societies now recommend carotid stenting as an alternative to
endarterectomy which raises the question of whether the ESVS guidelines are still valid. This review
addresses the validity of the ESVS guidelines that refer to carotid stenting based on the evidence
available today.
Methods: We conducted a review and meta-analysis based on the original ESVS guidelines paper and
articles published over the past 2 years.
Results: For symptomatic patients, surgery remains the best option, since stenting is associated with
a 61% relative risk increase of periprocedural stroke or death compared to endarterectomy. However,
centres of excellence in carotid stenting may achieve comparable results. In asymptomatic patients, there
is still no good evidence for any intervention because the stroke risk from an asymptomatic stenosis is
very low, especially with the best modern medical treatment. CREST and CAVATAS have veriﬁed that
mid-term stroke prevention after successful stenting is similar to endarterectomy. EVA-3S, SPACE, ICSS
and CREST have provided additional evidence regarding the role of age in choosing therapeutic modality.
The role of the cerebral protection devices is challenged by the imaging ﬁndings of small randomised
trials but supported by large systematic reviews.
Conclusions: The ESVS guidelines that refer to carotid stenting not only remain valid but also have been
further strengthened by the latest available clinical data. An update of these guidelines including all of
the recent evidence is needed to provide an objective and up-to-date interpretation of the data.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.: þ30 210 5831486.
ciety for Vascular Surgery. PublishIn April 2009, the European Society for Vascular Surgery pub-
lished clinical practice guidelines for the invasive treatment of
carotid disease.1 The document was based on the evidence avail-
able at that time. Two years thereafter, very little progress has beened by Elsevier Ltd. All rights reserved.
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contrary, carotid artery stenting (CAS) represents a ﬁeld of intense
clinical research, with several ongoing (ACT I, ACST-2 and SPACE-2)
or already published (ICSS, CREST, CAVATAS long-term) multi-
centre, randomised clinical trials. Accumulated knowledge over
these 2 years raises the question of whether the ESVS guidelines
that refer to carotid stenting are still valid. The question was
strengthened by the publication of the 2011 ASA/ACCF/AHA/AANN/
AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on
the management of patients with extracranial carotid and vertebral
artery disease recommending CAS as an alternative to endarter-
ectomy for symptomatic patients with carotid stenosis >50% as
well as for highly selected asymptomatic patients with carotid
stenosis >60%.2 The National Institute for Health and Clinical
Excellence has also concluded that current evidence on the safety
and efﬁcacy of carotid artery stent placement for symptomatic
extracranial carotid stenosis is adequate to support the use of this
procedure.3 More recently, however, the Society for Vascular
Surgery opined that CEA is preferred to CAS in the majority of
patients with carotid stenosis who are candidates for intervention.4
This reviewaswell asmeta-analysis addresses the validity of the
ESVS guidelines that refer to carotid stenting based on the evidence
available today.
Methods
A Medline search was performed using the term ‘carotid
stenting’, limited to articles published after July 2008, since the
ESVS guidelines paper was submitted on 11th August 2008. The last
search was performed on the 10th September 2011 and identiﬁed
35 reports from randomised controlled trials (RCTs) and 23 meta-
analyses. Ten reports from RCTs were selected based on their
relevance to the ESVS guidelines5e14 and nine meta-analyses,
including the ﬁve meta-analyses that were performed after the
publication of ICSS and CREST15e19 and four meta-analyses
addressing issues relevant to the ESVS guidelines.20e23 RCTs and
meta-analyses published before June 2008 were obtained from the
ESVS guidelines paper.1 Two reviewers, working independently,
extracted descriptive, methodological and outcome data from the
selected articles.
Random-effects meta-analysis was used to assess odds ratios
and the I2 statistic was used to assess heterogeneity of treatment
effect among trials.24 Average weighted incidence of events is
presented for both treatments. The pooled effect estimates wereFigure 1. Forest plot of stroke or death within 30 days of procedure (except for ICSS whe
patients submitted to CAS or CEA.calculated as the back-transformation of the weighted mean of the
transformed proportions, using DerSimonianeLaird weights. The
number needed to treat (NNT) was calculated as 1/(CEA group
event rate e CAS group event rate). In case of a negative group
event rate difference (CEA e CAS), we present number needed to
harm (NNH). Statistical analysis was performed with the use of the
Comprehensive Meta Analysis software, version 2.2.057 (Biostat
Inc., Englewood, NJ, USA).
Results
Invasive treatment recommendation 2. CAS in symptomatic patients
 The available level I evidence suggests that for symptomatic
patients, surgery is currently the best option [A].
The recommendation was based on a meta-analysis by The
Cochrane Collaboration of eight randomised trials comparing CEA
with CAS (CAVATAS, Kentucky, Leicester,Wallstent, SAPPHIRE, EVA-
3S, SPACE and BACASS) showing that surgery is associated with
lower stroke and death rate within 30 days of treatment (odds ratio
(OR): 1.39, 95% conﬁdence interval (CI): 1.05e1.84, P ¼ 0.02).25 The
results of two more trials were published thereafter, both of which
lending further support to the ESVS recommendation. The ICSS trial
showed that the risk of any stroke or death within 120 days of
randomisation was higher in the stenting group than in the
endarterectomy group (8.5% vs. 4.7%, hazard ratio (HR) 1.86,
1.26e2.74).26 Similarly, in the subgroup analysis of the symptom-
atic patients in the CREST trial, the periprocedural stroke or death
rate was 6.0% in the stenting group versus 3.2% in the endarterec-
tomy group (HR 1.89,1.11e3.21, P¼ 0.02).6 A trend towards a higher
rate of myocardial infarction (MI) in the group of symptomatic
patients undergoing CEA did not reach statistical signiﬁcance (1% in
the CAS group vs. 2.3% in the CEA group, HR 0.4, 0.18e1.11, P¼ 0.08).
If the results of ICSS and CREST are added in the meta-analysis
(Fig. 1), the OR in favour of CEA will be increased from 1.39 to
1.61 (95% CI: 1.14e2.28) and the statistical signiﬁcance from 0.02 to
0.007, meaning that, in symptomatic patients, CAS is associated
with a 61% relative risk (RR) increase of periprocedural stroke or
death compared to CEA. The average weighted risk of stroke or
death in symptomatic patients submitted to CAS is 7.4%, whereas in
patients submitted to CEA it is 5.2%. Consequently, the NNH is 47,
meaning that every 47 patients submitted to CAS instead of CEA
one extra stroke or death will occur.re events occurring within 120 days of randomization are reported) in symptomatic
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deemed less relevant to current clinical practice: the CAVATAS
trial,26 in which only 26% of patients received stents, the Leicester
trial,27 in which non-dedicated stents were used without routine
predilation and the Wallstent trial,28 the full details of which have
never been published and was performed when no dedicated
material was available for carotid stenting. The results, however, of
the meta-analysis remain virtually the same, even when these
three RCTs are excluded (OR: 1.62, 95% CI: 1.14e2.31, P ¼ 0.008).
Given the results of these meta-analyses, which are similar to
the results of the ﬁve most recent meta-analyses in the liter-
ature,15e19 it seems strange that the recommendations of different
societies about the treatment of symptomatic carotid stenoses by
CEA or CAS are rather contradictory. The controversy is based on
the different importance given to MI as an outcome measure. The
ESVS1 and the SVS4 guidelines are apparently based on the premise
that stroke prevention is the key determinant of practice and, in
this context, they recommend CEA rather than CAS for the majority
of symptomatic patients. On the other hand, the American Heart
Association/American Stroke Association (AHA/ASA)29 and the 14
societies’2 guidelines are based on the premise that MI is consid-
ered to be the equivalent of stroke and death in the primary end
point and, thus, their indications for CAS are more liberal.
Although in no way can an MI be disregarded as an outcome,
there are two points of concern raised by its inclusion in the
primary endpoint, as in the CREST trial. The ﬁrst point is that an
asymptomatic MI cannot be considered as an equivalent to death or
stroke and be given the same importance by being included in the
same, composite end point. The results of the CREST trial are
actually in support of this notion, showing that even minor strokes
had a signiﬁcant, adverse effect on physical health at 1 year,
according to the SF-36 physical component scale, whereas the
effect of periprocedural MI was not statistically signiﬁcant.6 On the
other hand, a post hoc analysis from the CREST showed that bothMI
and biomarker elevation only were independently associated with
increased future mortality.7 This ﬁnding, however, does not justify
the inclusion of asymptomatic MIs in a composite end point that
already includes mortality.
The second point of criticism is that, if asymptomatic MIs are to
be included in the primary end point, then asymptomatic cerebral
infarctions should be included as well. In a substudy of the ICSS,
50% of the patients in the stenting group and 17% of the patients in
the endarterectomy group had at least one new lesion detected on
post-treatment magnetic resonance imaging (MRI) scans done
a median of 1 day after treatment (adjusted OR 5.21, 95% CI
2.78e9.79; P < 0.0001).8 However, differences between CAS and
CEA in effect on cognition were not found to be statistically
signiﬁcant in the two participating centres that performed neuro-
psychological examinations before and 6 months after revascular-
isation.9 Thus, asymptomatic brain lesions detected by MRI after
a carotid intervention cannot be included in the same, composite
end point with other complications causing disability or death.
 Mid-term stroke prevention after successful CAS is similar to
CEA [A].
The recommendation was based on the mid-term outcomes of
EVA-3S and SPACE.10,11 The more recently published long-term
results of CAVATAS12 and the mid-term results of CREST6 are in
accordance with these data. The long-term results of the CAVATAS
trial showed that the 8-year incidence of ipsilateral non-
perioperative stroke was 11.3% in the CAS group versus 8.6% in
the CEA group (HR 1.22, 95% CI 0.59e2.54).12 Likewise, the CREST
trial showed that, after the periprocedural period, the 4-year inci-
dence of ipsilateral stroke was similarly lowwith CAS and with CEA(2.0% and 2.4%, respectively; P¼ 0.85).6 Because the life expectancy
of the patients included in CREST was 15 years after the procedure,
outcomes are being assessed out to 10 years and are awaited.
 CAS should be offered to symptomatic patients, if they are at
high risk for CEA, in high-volume centres with documented
low periprocedural stroke and death rates or inside an RCT [C].
The recommendation was based on experts’ opinion, with the
term ‘high risk for CEA’ referring mainly to adverse vascular and
local anatomic features, such as contralateral laryngeal nerve palsy,
previous radical neck dissection, cervical irradiation, prior CEA
(restenosis), high bifurcation or intracranial extension of a carotid
lesion.
The term ‘high-volume centres with low-procedural stroke and
death rates’ had not been sufﬁciently documented in the original
paper, but now there are sufﬁcient data, though not level A, to
support it. In a review of 18 599 CAS procedures, the stroke rate
after CAS was found to be signiﬁcantly different between low- and
high-volume hospitals (2.35% vs. 1.78%, respectively; P ¼ 0.02), as
well as between low- and high-volume practitioners (2.19% vs.
1.51%, P ¼ 0.02). The characterisation ‘high-volume’ was arbitrarily
granted to hospitals performing >30 CAS/year and practitioners
performing >15 CAS/year.30 Similarly, a systematic review of the
literature showed that, in active CAS units, it may take almost 2
years before the stroke/death rates fall below an arbitrary 5%
threshold.31
Invasive treatment recommendation 3. CAS in asymptomatic
patients
 It is advisable to offer CAS in asymptomatic patients only in
high-volume centres with documented low periprocedural
stroke and death rates or within well-conducted clinical
trials [C].
The recommendation was based on the fact that data on
asymptomatic patients were very weak, coming only from one
small randomised trial, comprising only 85 patients,32 and
a subgroup analysis of the SAPPHIRE trial, which was not pre-
speciﬁed.33 Both studies showed that CAS and CEA are equally
effective in preventing stroke and death in asymptomatic patients.
Another subgroup analysis from the more recently published
CREST trial showed similar ﬁndings. The rate of periprocedural
stroke or death in asymptomatic patients included in CREST was
2.5% in CAS versus 1.4% in CEA (OR 1.88, 0.79e4.42, P ¼ 0.15).6,13 No
statistically signiﬁcant difference was also found in the rate of MI
(1.2% vs. 2.2%, OR 0.55, 0.22e1.38, P ¼ 0.2), in the rate of any peri-
procedural stroke (2.5% vs. 1.4%, OR 1.88, 0.79e4.42, P ¼ 0.15) or in
the rate of the composite primary end point (any periprocedural
stroke, MI or death: 3.5% vs. 3.6%, OR 1.02, 0.55e1.86, P ¼ 0.96).6,13
A meta-analysis of the subgroup data from all trials that have
included asymptomatic patients (Fig. 2) shows that there is no
statistically signiﬁcantdifference in the strokeordeath ratebetween
CAS (pooled incidence 4.1%) and CEA (pooled incidence 3.0%) in
asymptomatic patients (OR 1.60, 0.84e3.02, P¼ 0.15). However, the
number of patients included in the meta-analysis is small to detect
a difference between4.1% and3.0%. It is also very interesting that the
OR in our meta-analysis was virtually the same in symptomatic
(1.61) and asymptomatic (1.60) patients submitted to CAS or CEA.
Further data from randomised trials on the outcomes of CAS versus
CEA in asymptomatic patients will not be available for several years
until the ongoing ACT-1 and ACST-2 trials are completed.
On the other hand, there is growing evidence that rates of
ipsilateral and any-territory stroke with medical intervention alone
Figure 2. Forest plot of stroke or death within 30 days of procedure in asymptomatic patients submitted to CAS or CEA.
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overlapping those of patients who underwent CEA in randomised
trials20,34 or contemporary series.35 The average annual risk of
ipsilateral stroke in asymptomatic patients with >50% stenosis was
>3% in 1985, but has fallen to approximately 0.5% in 2008.20 The
most recent, prospective, population-based study, recruiting
patients from 2002 to 2009 who were given intensive contempo-
rarymedical treatment, showed that the average annual event rates
on medical treatment were 0.34% for any ipsilateral ischaemic
stroke, 0% for disabling ipsilateral stroke and 1.78% for ipsilateral
transient ischaemic attack (TIA).36 Given this new evidence, current
vascular disease medical intervention alone may now be best for
stroke prevention associated with asymptomatic severe carotid
stenosis. Until the results of the SPACE-2 study, which is a three-
armed comparison among up-to-date best medical treatment,
CAS and CEA in patients with asymptomatic CAD, are available, the
role of CAS in asymptomatic patients will be questionable. TACIT
and CREST-2 trials are designed similar to SPACE-2 but have yet to
open or be funded.
Similar to the previously mentioned ﬁndings on the importance
of the ‘high volume’ operator and centre on the outcome of stenting
for symptomatic carotid stenosis, the value of the learning curve
and the operator’s experience has also been proven for the
asymptomatic patients. In a recently published analysis of the
CAPTURE-2 study, in 3388 asymptomatic non-octogenarian
subjects, an inverse relationship between event rates and hospital
patient volume, as well as between event rates and individual
operator volume, was observed; a threshold of 72 cases was found
to be necessary for consistently achieving a death and stroke rate of
<3% in this later-phase single-arm study.37Invasive treatment recommendation 4. Treatment options
inﬂuenced by medical co-morbidities
 For asymptomatic patients at ‘extremely’ high risk (several
medical co-morbidities at the same time), best medical treat-
ment might be the best option instead of invasive intervention
[C].
 CAS should not be offered to asymptomatic ‘high-risk’ patients
if the peri-interventional complication rate is >3% [C].
There is still no indication from the literature that a ‘high risk’
for surgery patient is also at ‘high risk’ for stroke if medically
treated. Therefore, a peri-interventional stroke or death risk of >3%
in ‘high-risk for surgery’ patients with asymptomatic carotid
stenosis cannot be accepted. CAS is associated to higher risk of embolisation in octogenar-
ians [B]. CEA is performed in octogenarians without increased
risk of embolisation andwith an acceptable rate of neurological
and cardiac complications [C].
The recommendation was based on several papers demon-
strating that octogenarians undergoing CAS are at a higher risk than
non-octogenarians for periprocedural complications, including
neurological events and death.38,39 The ﬁnding that the risk of CAS
is higher in older patients has been veriﬁed by several studies
published over the past 2 years, although the exact cut-off point of
age after which CAS is worse than CEA is still to be deﬁned. In the
CREST trial an interaction between age and treatment efﬁcacy was
detected, with a crossover at an age of approximately 70 years; CAS
tended to show greater efﬁcacy at younger ages, and CEA at older
ages.6
In accordance with these ﬁndings, a recently published pooled
analysis of EVA-3S, SPACE and ICSS showed that, in patients <70
years old, the 120-day stroke or death risk was 5.8% in CAS and 5.7%
in CEA (RR 1.00, 0.68e1.47), whereas in patients 70 years or older,
there was an estimated twofold increase in risk with CAS over CEA
(12.0% vs. 5.9%, RR 2.04, 1.48e2.82, interaction P ¼ 0.0053).21
Similar results were reported by the CAPTURE 2 trial which, as of
January 2009, had enrolled 5297 patients, 1166 of whom were
octogenarians.40 The death/stroke rate for the overall cohort was
3.3%; stroke rate was 2.7% (0.8% major, 1.9% minor). Death/stroke
rates were signiﬁcantly higher for octogenarians than non-
octogenarians (4.5% vs. 3.0%) as were stroke rates (3.8% vs. 2.4%).
An earlier meta-analysis of procedural stroke and death among
octogenarians undergoing CAS (826 patients) or CEA (7017
patients) had shown that octogenarians undergoing CAS had
a signiﬁcantly higher absolute risk of stroke than those undergoing
CEA (7% vs. 1.9%, P < 0.01), with no signiﬁcant difference in
mortality (2% vs. 1.1%, P ¼ 0.25) and a trend towards a lower rate of
MI (0.9% vs. 2.2%, P ¼ 0.08).23
Further studies are needed to show whether the suggested, by
the pooled analysis of EVA-3S, SPACE and ICSS, equivalence
between CEA and CAS in patients <70 years old will become a level
A recommendation. The main caveat is that the potentially higher
rate of recurrent stenosis after stenting compared to endarterec-
tomy may lead to an unfavourable long-term outcome in young
patients with a long life expectancy. So far, we have subgroup
analyses regarding the perioperative outcome of CAS versus CEA in
young patients, but we still do not have any analysis regarding the
mid- or long-term outcome in this particular group of patients.
Invasive treatment recommendation 13. Improving the CAS outcome
 Cerebral protection devices are probably beneﬁcial [C].
J.D. Kakisis et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 238e243242The recommendation was based on a systematic review of all
studies reporting on the incidence of CAS complications that were
published between 1990 and 2002,41 as well as on a subsequent
report by the Global Carotid Artery Stent Registry documenting
a 5.3e5.5% rate of stroke and death in cases performed without
protection, compared with 1.8e2.2% in cases performed with
cerebral protection.42
A randomised study of CAS with or without a distal cerebral
protection ﬁlter, published before the ESVS guidelines, had shown
that, contrary to the initial expectations, new MRI lesions devel-
oped in 72% of the cerebral protection group compared with 44% in
the no cerebral protection group (P ¼ 0.09).43 Most of these lesions
were silent, with the stroke rate being equal in the two groups
(11%). The major limitation of this study was the small number of
cases included (36 stenting procedures in 35 patients), which was
due to the reluctance of the patients to participate in a study with
no cerebral protection group.
Interestingly, the ﬁndings of this study were recently duplicated
by another randomised trial, which showed that ﬁlter-protected
CAS is associated with an increase in new lesions on diffusion-
weighted magnetic resonance imaging (29% vs. 18%) and signiﬁ-
cantly higher rates of total and particulate microembolisation on
transcranial Doppler (426.5 and 251.3 vs.165.2 and 92, respectively)
than unprotected CAS.14 This study was also very small (30
patients) and the differences in MRI lesions did not reach statistical
signiﬁcance. Larger studies are clearly warranted, though recruiting
for such studies is expected to be very difﬁcult, due to the already
established, widespread belief that, as the ESVS recommendation
states, “cerebral protection devices are probably of beneﬁt”.
This belief is also reinforced by the ﬁndings of the most recent
systematic review comparing stroke outcomes in protected and
unprotected CAS.22 The review included 134 articles reporting on
12 263 protected CAS patients and 11198 unprotected CAS patients.
Using pooled analysis, the RR for strokewas 0.62 (95% CI 0.54e0.72)
in favour of protected CAS. Subgroup analysis revealed a signiﬁcant
beneﬁt for protected CAS in both symptomatic (RR 0.67; 95% CI
0.52e0.56) and asymptomatic (RR 0.61; 95% CI 0.41e0.90) patients
(P < 0.05).
Conclusions
At this time, the latest available data have rather strengthened
the ESVS guidelines on the management of carotid artery disease.
CEA remains the gold standard, whereas CAS retains its role in
symptomatic patients at high risk for CEA, in the hands of expe-
rienced interventionalists and in high-volume centres with
documented low periprocedural event rates. The role of CAS in
asymptomatic patients is questionable. Since these conclusions are
in sharp contrast with those of other recently published guide-
lines, an update of the ESVS guidelines is needed to provide an
objective and up-to-date interpretation of the data. Although the
recommendations are not expected to drastically change, it is
important for the Society to provide new guidelines incorporating
the results of the recently published series on the natural history
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